ABSTRACT
Introduction: The hospital’s pharmacy is one of the most heavily used therapeu?c services and one of the few places where a significant amount of money is spent on recurrent purchases. This underlines the need of strategically planning, crea?ng, and arranging the pharmacy to ensure effec?ve clinical and administra?ve services. Materials and Methods:Inventory control techniques like ABC, VED and ABC-VED matrix analysis were used to evaluate the annual drug expenditure at drug store of Government Medical College & Hospital Jalgaon for the financial year 2019-20. Results:Total number of drugs in inventory in Government Medical College & Hospital Jalgaon in the year 2019-20 were 334 and the annual drug expenditure was 54040462/-. Category A comprised of 49 drugs (14.7%) for which annual drug expenditure was 37286500/- i.e. 69%. 87 drugs (26%) accoun?ng to 11324859/- (20.96%) were classified as category B drugs. Category C drugs included 198 drugs comprising 59.3% of total inventory and consumed 5429103/- i.e. 10.05% of total annual drug expenditure. 39 drugs (11.7%) were classified into vital/V category which accounted for 15257089/- i.e. 28.23% of annual drug expenditure, while essen?al/E category included 127 (38%) drugs for which 30161684/- (55.81%) was incurred for their procurement. 168 (50.3%) drugs accoun?ng to 8621689/- (15.95% of total annual drug expenditure). Conclusion:The applica?on of inventory control strategies such as ABC, VED, and the ABC-VED Matrix will help in significant improvements in pa?ent care.
ABSTRACT
roduction: The recent prevalence of dermatophytosis in India ranges from 36.6 to 78.4%. Itraconazole is commonly usedsystemic antifungal to treat dermatophytosis.Objective: The objective of the present study was to evaluate the effectiveness and safety of itraconazole given 100 mg twicedaily for the treatment of dermatophytosis.Materials and Methods: The present retrospective questionnaire-based survey was done, wherein dermatologists and generalphysicians were given survey questionnaire. Data analysis up to 4 weeks of treatment with itraconazole was considered forthis study. Efficacy evaluation was considered as percentage of patients achieving clinical cure.Results: A total of 150 doctors completed the survey involving 1100 patients. Out of 1100 patients, 341 patients (31%)responded well to topical therapy alone and were considered as clinically cured as per medical records. In remaining patientswho did not respond well to topical monotherapy, itraconazole was found to be added in 652 patients as 100 mg twice daily for4 weeks. Of these, 456 patients (70%) responded well to therapy in 4 weeks and were considered as clinically cured. Amongthe topical antifungals coprescribed with itraconazole, luliconazole was most commonly prescribed (49%). On comparison ofclinical cure rates in patients who received topical antifungal monotherapy (31%) and itraconazole cotherapy (70%), it was foundthat itraconazole cotherapy was better and the difference between the two therapies was statistically significant (P = 0.001).Conclusion: From the findings of the present analysis, clinical cure rates obtained with itraconazole were more than satisfactory.Although the standard duration of therapy ranges from 1 to 2 weeks, long-term treatment is warranted and that is with topicalantifungals and other supportive measures.
ABSTRACT
After hemorrhage, anemia is the most common cause of maternal mortality and leading cause of maternal morbidity in India. Theprevalence rates of anemia in pregnancy in India is estimated to be >50%. Iron deficiency anemia (IDA) is the most commontype of anemia in pregnancy in India, which I can be as high as 80–90%.Aims and Objectives: The present survey was initiated in pursuit of analyzing the effectiveness and safety of oral ferricpyrophosphate (FPP) formulation given once to twice daily for treatment and prophylaxis of IDA in pregnancy.Materials and Methods: This was a questionnaire-based retrospective survey. Each gynecologist was given this survey bookletcontaining questionnaire. Clinical response was assessed by measuring rise in mean hemoglobin (Hb) levels at baseline, week4, and week 8, after giving oral FPP formulation for 8 weeks.Results: A total of 60 gynecologists participated and completed the survey, which involved 1073 pregnant subjects and patientssuffering from IDA (864 patients, i.e., 80%). Mean Hb level at baseline was found to be 8.98 g/dl, 10.03 at week 4, and 10.99 atweek 8. Thus, rise of Hb from baseline to week 8 was found to be 2.01 g/dl. Adverse events were reported in only 10 patients(<0.09%), none requiring discontinuation of therapy. 98% of the participants agreed good acceptability of oral FPP formulation.Conclusion: Findings of the present survey suggests that oral FPP formulation therapy can serve as potent choice of therapyfor IDA in pregnancy, both therapeutically and prophylactically
ABSTRACT
Background: Hypertension and diabetes mellitus are both chronic disorders and when they occur as co-morbidities create havoc by presenting with a plethora of morbidity and mortality. Both require drug treatment over a long period of time, which calls for stringent analysis of prescribing trends of the same. Objectives: The present study was intended to analyze prescribing pattern and establish prescribing trends of anti-hypertensive drugs (AHD) in hypertensive diabetic patients. Methods: The present study was a record based, randomized, non-interventional study of 2 years duration conducted at a tertiary care hospital of central India. Prescriptions from 400 case records of hypertensive diabetics were obtained from the medical record section. Demographic details, blood pressure, and AHDs prescribed were systematically entered in pre-validated case record form. All data were thoroughly analyzed for fallacies and appropriateness. Results: Among 400 patients, 221 were males, and 179 were females. Monotherapy was used in 366 (91.5%) patients while combination therapy was used in 34 (8.5%) patients. Most commonly used combination was angiotensin converting enzyme inhibitor (ACEI)+calcium channel blocker (CCB), while in monotherapy CCB≥ACEI>beta blocker>diuretic>angiotensin II receptor blocker were most commonly prescribed. Conclusion: The present study represents trend and attitude of physicians in prescribing AHDs. On comparing with Joint National Committee 7 guidelines, the majority of the cases deviated from the guidelines, mostly in a choice of AHDs and Fixed dose combination.
ABSTRACT
Background: Diabetes mellitus in early age is on the alarming rise in India, requiring lifelong treatment. There is a wide range of variation in the prices of antidiabetic drugs marketed in India. Hence, we decided to study price variations in the oral antidiabetic drugs available, either singly or in combination, and number of manufacturing companies for each, and to evaluate the difference in cost of different brands of same active drug by calculating percentage variation of cost. Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July-October 2014 and “Indian Drug Review” July 2014. The difference in the maximum and minimum price of the same drug, manufactured by different pharmaceutical companies and percentage variation in price was calculated. Results: Percentage price variation among different group of drugs was found to be as follows: in sulfonylureas, it was highest in glimepiride 2 mg 836.44%, among biguanides - metformin 500 mg 245.55%, among thiazolidionedionespioglitazone 15 mg 600%, among α glucosidase inhibitors - voglibose 284.61% and meglitinides - repaglinide 0.5 mg 181.40%. Among combination therapy glimepiride 1 mg + metformin 500 mg 366.66%, pioglitazone + metformin 207.51%, pioglitazone + glimepiride 268.42% showed maximum variation in price. Conclusion: The average percentage price variation of different brands of the same oral antidiabetic drug manufactured in India is very wide. The appropriate changes in the government policy, sensitizing the prescribers about cost of therapy and proper management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative economic consequences.